Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01355965 · ClinicalTrials.gov registry record · Phase 1
Autologous Redirected RNA Meso-CIR T Cells
A Phase 1 study of Malignant Pleural Mesothelioma, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01355965 is a Phase 1 study of Malignant Pleural Mesothelioma that has completed, run by University of Pennsylvania. The registered enrollment target is 18 participants, below the 87-participant average among 6 other Malignant Pleural Mesothelioma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01355965, a Phase 1 study of Malignant Pleural Mesothelioma, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and manufacturing feasibility of IV autologous chimeric immune receptor (CIR) T cells transfected with anti-mesothelin messenger RNA (mRNA) expressing a single chain antibody variable fragment linked to the intracellular CD 3 zeta T cell receptor domain and the 4-1BB costimulatory domain.
Conditions Studied
Interventions
- BIOLOGICAL Autologous T cells
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01355965
The ClinicalTrials.gov registry entry for NCT01355965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 6 other Malignant Pleural Mesothelioma trials with a reported enrollment target (79% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Pleural Mesothelioma appearing as the primary indexed condition, and to 1 intervention - of which Autologous T cells is the first listed.
NCT01355965 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01355965 about?
NCT01355965 is a clinical study titled "Autologous Redirected RNA Meso-CIR T Cells". To determine the safety and manufacturing feasibility of IV autologous chimeric immune receptor (CIR) T cells transfected with anti-mesothelin messenger RNA (mRNA) expressing a single chain antibody variable fragment linked to the intracellular CD 3 zeta T cell receptor domain and the 4-1BB costimul...
What is the current status of trial NCT01355965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-05. Estimated completion is 2015-10.
What conditions does trial NCT01355965 study?
This clinical trial studies the following conditions: Malignant Pleural Mesothelioma.
What interventions are being tested in trial NCT01355965?
The interventions under investigation include: Autologous T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01355965?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01355965 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Pleural Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
COMPLETED · Phase 1
-
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
RECRUITING · NA
-
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 3
-
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.